2011 聚乙二醇干扰素用于HDV.pdf

T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta Heiner Wedemeyer, M.D., Cihan Yurdaydìn, M.D., George N. Dalekos, M.D., Andreas Erhardt, M.D., Yilmaz Çakaloğlu, M.D., Halil Değertekin, M.D., Selim Gürel, M.D., Stefan Zeuzem, M.D., Kalliopi Zachou, M.D., Hakan Bozkaya, M.D., Armin Koch, M.D., Thomas Bock, M.D., Hans Peter Dienes, M.D., and Michael P. Manns, M.D., for the HIDIT Study Group* A bs tr ac t Background From Hannover Medical School, Han­ Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in nover (H.W., A.K., M.P.M.); Heinrich Heine the most severe form of viral hepatitis. There is no currently approved treatment. We University, Düsseldorf (A.E.); Johann Wolfgang Goethe University, Frankfurt investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa- (S.Z.); Robert Koch Institute, Berlin (T.B.); 2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone. and University Köln, Cologne (H.P.D.) — all in Germany; the University of Ankara Methods Medical School (C.Y., H.B.) and Ufuk Uni­ We conducted a randomized trial in which 31 patients with HDV infection received versity Medical School (H.D.), Ankara;